2019 NCCN Conference

Updated NCCN Guideline Strongly Recommends Germline Testing for All Patients with Pancreatic Cancer

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference, Pancreatic Cancer

Orlando, FL—Germline testing should now be considered for any patient with pancreatic cancer, and molecular analysis of tumors should be considered in patients with metastatic disease, according to the updated National Comprehensive Cancer Network (NCCN) guideline for pancreatic cancer presented at the 2019 NCCN Conference. [ Read More ]

New Targeted Therapies for Metastatic Colorectal Cancer Recommended in the Updated NCCN Guideline

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference, Colorectal Cancer

Orlando, FL—A growing number of targeted therapies and immunotherapies are now recommended in the updated National Comprehensive Cancer Network (NCCN) guideline for metastatic colorectal cancer (CRC). New first-line immunotherapy options for patients with mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) CRC are also listed in the new guideline. [ Read More ]

Assessment of Opioid Misuse and Abuse Should Be Part of Cancer Pain Management

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference

Orlando, FL—Maintaining patient safety and minimizing the risks for opioid misuse and abuse in the management of cancer pain require proper assessment and new strategies for pain management that include integrative interventions, according to Judith A. Paice, PhD, RN, Director, Cancer Pain Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago. She discussed this topic at the 2019 National Comprehensive Cancer Network (NCCN) Conference. [ Read More ]

Expert Panel Discusses Access to CAR T-Cell Therapy

Wayne Kuznar

June 2019, Vol 10, No 3 - 2019 NCCN Conference

Orlando, FL—With price tags approaching $1 million or more for delivery of certain immune cell therapies, new payment models will be needed to ensure access to these therapies and to further innovations. This was a key issue addressed at a roundtable discussion at the 2019 National Comprehensive Cancer Network (NCCN) Conference. Ensuring access to chimeric antigen receptor (CAR) T-cell therapy emerged as a top area of concern. [ Read More ]

Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy

Wayne Kuznar

April 2019, Vol 10, No 2 - 2019 NCCN Conference, Leukemia

Orlando, FL—The discontinuation of a tyrosine kinase inhibitor (TKI) is considered safe and appropriate in consenting patients with chronic-phase chronic myeloid leukemia (CML) under specific circumstances and with careful molecular monitoring, according to the updated National Comprehensive Cancer Network (NCCN) management guideline for CML. [ Read More ]

Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease

Wayne Kuznar

April 2019, Vol 10, No 2 - 2019 NCCN Conference, Breast Cancer

Orlando, FL—Options for the treatment of patients with advanced hormone receptor (HR)-positive, HER2­negative breast cancer are expanding. The updated National Comprehensive Cancer Network (NCCN) guideline (version 1.2019) for the management of invasive breast cancer is focused on HR-positive, HER2-negative disease. William J. Gradishar, MD, Director, Maggie Daley Center for Women’s Cancer Care, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, discussed the updated guideline at the NCCN 2019 Conference. [ Read More ]

Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing

Wayne Kuznar

April 2019, Vol 10, No 2 - 2019 NCCN Conference

Orlando, FL—The updated National Comprehensive Cancer Network (NCCN) guideline for non–small-cell lung cancer (NSCLC; version 3.2019) is focused on improving patient outcomes with immunotherapy. Pembrolizumab (Keytruda) is recommended as the preferred first-line immune checkpoint inhibitor for patients with ≥50% of tumor cells that express PD-L1. First-line immunother­apy is restricted to NSCLC without EGFR or ALK mutations. [ Read More ]